{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T22:27:28Z","timestamp":1783636048394,"version":"3.55.0"},"reference-count":61,"publisher":"Wiley","issue":"16","license":[{"start":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T00:00:00Z","timestamp":1650585600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["British J Pharmacology"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:sec><jats:title>Background and Purpose<\/jats:title><jats:p>Circulating cytokines are central pathological mediators of inflammatory autoimmune diseases like rheumatoid arthritis. Immunological diversity in patients might contribute to inadequate responses to biological drugs. To address this therapeutic challenge, we developed a mathematical model that simultaneously describes temporal patterns of drug disposition for several biologics and their corresponding targeted cytokines, which were linked to triggering inflammatory responses.<\/jats:p><\/jats:sec><jats:sec><jats:title>Experimental Approach<\/jats:title><jats:p>A modelling framework was applied to rheumatoid arthritis\u2010relevant cytokines regulating C\u2010reactive protein (CRP) as an inflammatory marker. Clinical data were extracted from the literature for anakinra, canakinumab, infliximab, secukinumab and tocilizumab, along with their corresponding cytokines, interleukin\u20101 receptor antagonist, IL\u20101\u03b2, tumour necrosis factor \u03b1 (TNF\u03b1), IL\u201017A and IL\u20106 receptor (IL\u20106R). Based on prior knowledge of regulatory mechanisms, cytokines were integrated with CRP profiles.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Results<\/jats:title><jats:p>The model well captured all serum concentration\u2013time profiles of cytokines and CRP ratios to respective baselines following drug treatment with good precision. On external validation, reasonable model performance on CRP dynamics, including rebound effects, was confirmed with clinical data not used in model development. Model\u2010based simulations demonstrated that serum infliximab concentrations were accurately recapitulated in both a dose\u2010 and baseline TNF\u03b1\u2010dependent manner. Furthermore, high baseline profiles of both IL\u20101\u03b2 and\/or targeted cytokines could be predictors of poor responses to biologics targeting TNF\u03b1 and IL\u20106R, although the impact of IL\u20101\u03b2 must be carefully interpreted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Implication<\/jats:title><jats:p>Our model provides a quantitative platform to guide targeting and dosing strategies, including combination and\/or sequential therapy, according to distinct baseline cytokine patterns in rheumatoid arthritis patients.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bph.15845","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T02:53:41Z","timestamp":1648695221000},"page":"4063-4077","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Systems model identifies baseline cytokine concentrations as potential predictors of rheumatoid arthritis inflammatory response to biologics"],"prefix":"10.1111","volume":"179","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0519-6543","authenticated-orcid":false,"given":"Tomohisa","family":"Nakada","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, SUNY  Buffalo New York USA"},{"name":"Sohyaku. Innovative Research Division Mitsubishi Tanabe Pharma Corporation  Yokohama Kanagawa Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0440","authenticated-orcid":false,"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences University at Buffalo, SUNY  Buffalo New York USA"},{"name":"Enhanced Pharmacodynamics, LLC  Buffalo New York USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,22]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Actemra (Tocilizumab) Injection. (2010).US Food & Drug Administration. Drug Approval Package Clinical Pharmacology and Biopharmaceutics Review. Retrieved fromhttps:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/125276s000ClinPharmR.pdf"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2012.6"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1393"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15541"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2438"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40070"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000725"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gene.6363766"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203523"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390704"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-014-9374-0"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev269"},{"issue":"3","key":"e_1_2_12_14_1","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","article-title":"Regulation of cytokines, cytokine inhibitors, and acute\u2010phase proteins following anti\u2010TNF\u2010\u03b1 therapy in rheumatoid arthritis","volume":"163","author":"Charles P.","year":"1999","journal-title":"Journal of Immunology"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.074807"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2013.8"},{"key":"e_1_2_12_17_1","unstructured":"Cosentyx (Secukinumab) Injection. (2014).Japanese Pharmaceuticals and Medical Devices Agency. Drug Approval Package Summary of Clinical Pharmacology Studies. Retrieved fromhttps:\/\/www.pmda.go.jp\/drugs\/2014\/P201400171\/index.html"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14153"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-18-2225"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0277-8"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(88)90185-7"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(94)90628-9"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(94)90632-7"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.immunol.19.1.163"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci119488"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23940"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-011-9227-z"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-009-9125-9"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.731877"},{"key":"e_1_2_12_30_1","unstructured":"Ilaris (Canakinumab) Injection. (2011).Japanese Pharmaceuticals and Medical Devices Agency. Drug Approval Package Summary of Clinical Pharmacology Studies. Retrieved fromhttps:\/\/www.pmda.go.jp\/drugs\/2011\/P201100163\/index.html"},{"issue":"8","key":"e_1_2_12_31_1","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.4049\/jimmunol.154.8.4081","article-title":"Neutralization of endogenous IL\u20106 suppresses induction of IL\u20101 receptor antagonist","volume":"154","author":"Jordan M.","year":"1995","journal-title":"Journal of Immunology"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20082481"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000458"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.134"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m117.818559"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1014414520282"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22033"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.29.3.170"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2015.171"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxr077"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2017.01.004"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.08.004"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.07.018"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-015-3379-x"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2018.07.014"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.112.122556"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(17)32247-x"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpc.2009.09.018"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.144063"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.121389"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13075-017-1308-y"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(08)60453-5"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00074.2003"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.153023"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-201069"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/conmed-2018-000002"},{"issue":"3","key":"e_1_2_12_59_1","first-page":"315","article-title":"The early clinical course of infliximab treatment in rheumatoid arthritis: Results from the REMARK observational study","volume":"32","author":"Westhovens R.","year":"2014","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-009-9142-8"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(03)00094-8"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12622"}],"container-title":["British Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.15845","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bph.15845","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bph.15845","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T13:50:17Z","timestamp":1692712217000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bph.15845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,22]]},"references-count":61,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1111\/bph.15845"],"URL":"https:\/\/doi.org\/10.1111\/bph.15845","archive":["Portico"],"relation":{},"ISSN":["0007-1188","1476-5381"],"issn-type":[{"value":"0007-1188","type":"print"},{"value":"1476-5381","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,22]]},"assertion":[{"value":"2021-09-14","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}